Lee's Pharmaceutical Holdings Ltd (00950) has issued a positive profit alert, indicating that the group expects to report an audited net profit attributable to shareholders of between approximately HK$85 million and HK$95 million for the six months ending June 30, 2026.

This compares to a net profit of roughly HK$67.2 million recorded for the corresponding period ended June 30, 2025, according to a company filing.

The anticipated improvement in interim results is attributed primarily to two key factors: an increase in the group's revenue and a better overall gross profit margin. The margin enhancement stems from a more favorable product mix, which includes a larger contribution from higher-margin specialty and in-licensed products, along with continued gains in manufacturing efficiency across its production sites.

The positive impact of these combined elements is expected to more than offset higher research and development expenses, selling and distribution costs, and administrative charges—including costs related to the group's newly consolidated U.S. business operations during the reporting period.